$OMER
OMEROS CORP

2022 Q2 Form 10-Q Financial Statement

#000155837022008120 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Cost Of Revenue $0.00
YoY Change -100.0%
Gross Profit $0.00
YoY Change -100.0%
Gross Profit Margin
Selling, General & Admin $13.92M $10.96M $54.84M
YoY Change -10.09% -39.29% 206.38%
% of Gross Profit
Research & Development $23.52M $24.09M $118.8M
YoY Change -23.99% -25.9% 348.89%
% of Gross Profit
Depreciation & Amortization $191.0K $278.0K $324.0K
YoY Change -46.2% -28.72% -19.0%
% of Gross Profit
Operating Expenses $37.44M $24.09M $173.6M
YoY Change 21.01% -25.9% 291.38%
Operating Profit -$37.44M -$35.05M -$173.6M
YoY Change 55.89% -22.62% 413.42%
Interest Expense -$4.927M $4.941M -$19.67M
YoY Change -200.35% 0.9% 146.17%
% of Operating Profit
Other Income/Expense, Net $670.0K $493.0K $1.740M
YoY Change 101.2% 17.94% 370.27%
Pretax Income -$41.70M -$39.49M -$191.5M
YoY Change -16.92% 12.55% 362.34%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$30.85M -$33.01M $194.2M
YoY Change 7.89% -5.92% -621.11%
Net Earnings / Revenue
Basic Earnings Per Share -$0.49 -$0.53
Diluted Earnings Per Share -$491.8K -$0.53 $3.116M
COMMON SHARES
Basic Shares Outstanding 62.73M 62.72M 62.54M
Diluted Shares Outstanding 62.73M 62.72M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $122.6M $142.2M $157.3M
YoY Change 66.39% 41.53% 16.49%
Cash & Equivalents $14.14M $9.000M $100.8M
Short-Term Investments $108.4M $133.3M $56.46M
Other Short-Term Assets $11.89M $7.623M $8.216M
YoY Change 100.54% 27.05% -25.98%
Inventory
Prepaid Expenses
Receivables $57.46M $59.96M $80.82M
Other Receivables $810.0K $408.0K $1.650M
Total Short-Term Assets $192.7M $210.2M $248.0M
YoY Change 71.46% 58.68% 63.9%
LONG-TERM ASSETS
Property, Plant & Equipment $25.05M $24.36M $30.01M
YoY Change -21.06% -10.43% 6.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.054M $1.054M $1.054M
YoY Change -16.28% -41.44% -38.0%
Total Long-Term Assets $152.9M $159.0M $171.3M
YoY Change 363.52% 449.14% 475.7%
TOTAL ASSETS
Total Short-Term Assets $192.7M $210.2M $248.0M
Total Long-Term Assets $152.9M $159.0M $171.3M
Total Assets $345.6M $369.3M $419.3M
YoY Change 137.73% 128.73% 131.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.88M $7.345M $13.40M
YoY Change 14.46% -36.12% 219.12%
Accrued Expenses $27.63M $23.80M $33.13M
YoY Change -17.09% -15.41% 15.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $38.50M $35.07M $51.79M
YoY Change -19.28% -19.27% 40.98%
LONG-TERM LIABILITIES
Long-Term Debt $314.4M $313.9M $313.5M
YoY Change 0.57% 0.55% 32.26%
Other Long-Term Liabilities $25.48M $25.22M $30.24M
YoY Change -18.86% -9.29% 8.0%
Total Long-Term Liabilities $339.8M $339.1M $343.7M
YoY Change -1.21% -0.26% 29.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $38.50M $35.07M $51.79M
Total Long-Term Liabilities $339.8M $339.1M $343.7M
Total Liabilities $378.3M $374.2M $395.5M
YoY Change -3.41% -2.4% 31.04%
SHAREHOLDERS EQUITY
Retained Earnings -$716.1M -$683.1M
YoY Change -21.51% -21.72%
Common Stock $711.2M $706.9M
YoY Change 3.0% -5.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$32.70M -$4.925M $23.78M
YoY Change
Total Liabilities & Shareholders Equity $345.6M $369.3M $419.3M
YoY Change 137.73% 128.73% 131.59%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$30.85M -$33.01M $194.2M
YoY Change 7.89% -5.92% -621.11%
Depreciation, Depletion And Amortization $191.0K $278.0K $324.0K
YoY Change -46.2% -28.72% -19.0%
Cash From Operating Activities -$19.47M -$15.19M -$18.21M
YoY Change -29.45% -62.26% -1.06%
INVESTING ACTIVITIES
Capital Expenditures -$103.0K $0.00 -$74.00K
YoY Change 14.44% -100.0%
Acquisitions
YoY Change
Other Investing Activities $24.84M -$76.81M $112.5M
YoY Change -18.53% -332.77% 1307.91%
Cash From Investing Activities $24.74M -$76.81M $112.4M
YoY Change -18.63% -332.87% 1305.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -99.00K 161.0K -810.0K
YoY Change -111.63% -97.22% 376.47%
NET CHANGE
Cash From Operating Activities -19.47M -15.19M -18.21M
Cash From Investing Activities 24.74M -76.81M 112.4M
Cash From Financing Activities -99.00K 161.0K -810.0K
Net Change In Cash 5.173M -91.85M 93.39M
YoY Change 41.3% 6135.23% -982.73%
FREE CASH FLOW
Cash From Operating Activities -$19.47M -$15.19M -$18.21M
Capital Expenditures -$103.0K $0.00 -$74.00K
Free Cash Flow -$19.37M -$15.19M -$18.14M
YoY Change -29.59% -62.27% -1.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.10
CY2021Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.24
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62724775
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61928511
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001285819
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62628855
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62730015
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.63
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.81
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-34475
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
OMEROS CORPORATION
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WA
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1663741
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
201 Elliott Avenue West
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98119
CY2022Q1 dei City Area Code
CityAreaCode
206
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
676-5000
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2022Q1 dei Trading Symbol
TradingSymbol
OMER
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
62730015
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8963000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100808000
CY2022Q1 us-gaap Short Term Investments
ShortTermInvestments
133271000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
56458000
CY2022Q1 omer Contract Royalty Asset Current
ContractRoyaltyAssetCurrent
44110000
CY2021Q4 omer Contract Royalty Asset Current
ContractRoyaltyAssetCurrent
44319000
CY2022Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
16255000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
38155000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7623000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8216000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
210222000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
247956000
CY2022Q1 omer Contract Royalty Asset Noncurrent
ContractRoyaltyAssetNoncurrent
133625000
CY2021Q4 omer Contract Royalty Asset Noncurrent
ContractRoyaltyAssetNoncurrent
140251000
CY2022Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1453000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1731000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22909000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28276000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1054000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1054000
CY2022Q1 us-gaap Assets
Assets
369263000
CY2021Q4 us-gaap Assets
Assets
419268000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
7345000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13400000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23796000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33134000
CY2022Q1 omer Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
3925000
CY2021Q4 omer Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
5255000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
35066000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
51789000
CY2022Q1 omer Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
24296000
CY2021Q4 omer Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
29126000
CY2022Q1 us-gaap Senior Long Term Notes
SeniorLongTermNotes
313904000
CY2021Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
313458000
CY2022Q1 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
922000
CY2021Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
1115000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62730015
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-4925000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62628855
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
627000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
626000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
710593000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
706288000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-716145000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-683134000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
23780000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
369263000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
419268000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24087000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32504000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10959000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12786000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
35046000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
45290000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-35046000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-45290000
CY2022Q1 us-gaap Interest Expense
InterestExpense
4941000
CY2021Q1 us-gaap Interest Expense
InterestExpense
4897000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
493000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
418000
CY2022Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-39494000
CY2021Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-49769000
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
6483000
CY2021Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
14679000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-33011000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-35090000
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.63
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.81
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.10
CY2021Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.24
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62724775
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61928511
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-120752000
CY2021Q1 omer Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
6333000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
278000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
390000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
241000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3271000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-35090000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-221955000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
23780000
CY2022Q1 omer Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
414000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3892000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-33011000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-4925000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-33011000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-35090000
CY2022Q1 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
454000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3892000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3271000
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
446000
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
396000
CY2022Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-21900000
CY2021Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
20985000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-592000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5202000
CY2022Q1 omer Increase Decrease In Contract Royalty Asset Current
IncreaseDecreaseInContractRoyaltyAssetCurrent
-6835000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-15671000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6562000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15193000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40254000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
83013000
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
3000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
6200000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
33000000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-76813000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
32985000
CY2022Q1 omer Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
414000
CY2021Q1 omer Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
6333000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
253000
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
296000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
241000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
161000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5796000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-91845000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1473000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100808000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10501000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8963000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9028000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
5967000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
5995000
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Omeros Corporation (“Omeros,” the “Company” or “we”) is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic diseases, including complement-mediated diseases and cancers related to dysfunction of the immune system, as well as addictive and compulsive disorders. We marketed our first drug product, OMIDRIA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (phenylephrine and ketorolac intraocular solution) 1% / 0.3% for use during cataract surgery or intraocular lens replacement in the United States (the “U.S.”) until we sold OMIDRIA and related business assets on December 23, 2021 (see “Sale of OMIDRIA Assets” below for additional information). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our drug candidate narsoplimab is the subject of a biologics license application (“BLA”) pending before the U.S. Food and Drug Administration (“FDA”) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (“HSCT-TMA”). On October 18, 2021, we announced the receipt of a Complete Response Letter (“CRL”) from FDA regarding the BLA. In the CRL, FDA expressed difficulty in estimating the treatment effect of narsoplimab in HSCT-TMA and asserted that additional information will be needed to support regulatory approval. In February 2022, we had a Type A end-of-review meeting with FDA to discuss the CRL, including each of the review issues that FDA identified as presenting difficulties interpreting the treatment response in the pivotal trial. Although we feel that we adequately addressed all of the issues noted in the CRL, the meeting minutes included a number of the review division’s critiques that we believe had already been addressed and/or were inaccurate. As a result, we currently plan to submit a Formal Dispute Resolution Request. Formal dispute resolution is an official pathway that enables a sponsor to appeal a decision by an FDA review division to a higher authority within FDA, in this case the Office of New Drugs. Our request is for regular approval based on the data in our existing BLA. We continue to believe that our BLA, as submitted, merits approval and that the data meet or exceed the threshold for substantial evidence of effectiveness; however, there can be no assurances that the Formal Dispute Resolution process will result in approval of our BLA, will provide a clear path to resubmission of our BLA, or that any identified path to BLA resubmission will be satisafactory in terms of the information, time and/or expenditure required. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We also have multiple late-stage clinical development programs in our pipeline, which are focused on: complement-mediated disorders, including immunoglobulin A (“IgA”) nephropathy, atypical hemolytic uremic syndrome (“aHUS”) and COVID-19.</p>
CY2022Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
142200000
CY2022Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
16300000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-33000000.0
CY2022Q1 us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
4200000
CY2022Q1 omer Maximum Aggregate Offering Price
MaximumAggregateOfferingPrice
150000000.0
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include OMIDRIA contract royalty asset valuation, stock-based compensation expense, and accruals for clinical trials and manufacturing of drug product. We base our estimates on historical experience and on various other factors, including the impact of the COVID-19 pandemic, that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</p>
CY2022Q1 omer Contract Royalty Asset Noncurrent
ContractRoyaltyAssetNoncurrent
133625000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5034168
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8394872
CY2021Q4 omer Contract Royalty Asset Noncurrent
ContractRoyaltyAssetNoncurrent
140251000
CY2022Q1 omer Contract Royalty Asset Current
ContractRoyaltyAssetCurrent
44110000
CY2021Q4 omer Contract Royalty Asset Current
ContractRoyaltyAssetCurrent
44319000
CY2022Q1 omer Contract Royalty Asset
ContractRoyaltyAsset
177735000
CY2021Q4 omer Contract Royalty Asset
ContractRoyaltyAsset
184570000
CY2022Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
15847000
CY2021Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
36505000
CY2022Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
408000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1650000
CY2022Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
16255000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
38155000
CY2021Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
2000000.0
CY2022Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
10764000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
10764000
CY2022Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
9311000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
9033000
CY2022Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1453000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1731000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6555000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
7455000
CY2022Q1 omer Accrued Contract Research Costs
AccruedContractResearchCosts
4492000
CY2021Q4 omer Accrued Contract Research Costs
AccruedContractResearchCosts
3916000
CY2022Q1 us-gaap Interest Payable Current
InterestPayableCurrent
3703000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
5172000
CY2022Q1 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
3408000
CY2021Q4 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
2430000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2503000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3706000
CY2022Q1 omer Accrued Sales Rebates Fees And Discounts Current
AccruedSalesRebatesFeesAndDiscountsCurrent
1727000
CY2021Q4 omer Accrued Sales Rebates Fees And Discounts Current
AccruedSalesRebatesFeesAndDiscountsCurrent
8442000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1408000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2013000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23796000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33134000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9000000.0
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100800000
CY2022Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2021 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
320030000
CY2022Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
6126000
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
313904000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
320030000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
6572000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
313458000
CY2022Q1 omer Number Of Options To Extend Lease Term
NumberOfOptionsToExtendLeaseTerm
2
CY2022Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2022Q1 omer Decrease In Right Of Use Asset Due To Early Operating Lease Termination
DecreaseInRightOfUseAssetDueToEarlyOperatingLeaseTermination
4700000
CY2022Q1 omer Decrease In Lease Liability Due To Early Operating Lease Termination
DecreaseInLeaseLiabilityDueToEarlyOperatingLeaseTermination
5200000
CY2022Q1 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
500000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1196000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1583000
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
197000
CY2021Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
323000
CY2022Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
56000
CY2021Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
63000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
860000
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
813000
CY2022Q1 us-gaap Sublease Income
SubleaseIncome
491000
CY2021Q1 us-gaap Sublease Income
SubleaseIncome
418000
CY2022Q1 us-gaap Lease Cost
LeaseCost
1818000
CY2021Q1 us-gaap Lease Cost
LeaseCost
2364000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1803000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1628000
CY2022Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
253000
CY2021Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
354000
CY2022Q1 omer Long Term Purchase Commitment Termination Fee
LongTermPurchaseCommitmentTerminationFee
31000000.0
CY2021Q1 omer Cashless Exercise Of Warrants
CashlessExerciseOfWarrants
43115
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
200000
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
23.00
CY2022Q1 omer Share Based Payment Arrangement Expense Continuing Operations
ShareBasedPaymentArrangementExpenseContinuingOperations
3892000
CY2021Q1 omer Share Based Payment Arrangement Expense Continuing Operations
ShareBasedPaymentArrangementExpenseContinuingOperations
3060000
CY2021Q1 omer Share Based Payment Arrangement Expense Discontinuing Operations
ShareBasedPaymentArrangementExpenseDiscontinuingOperations
211000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3892000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3271000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12709887
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.61
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
17884
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.74
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
101160
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.10
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
189010
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
14.29
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12437601
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.65
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y3M18D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
12139058
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12.61
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y2M12D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
15000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
9601612
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.19
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y3M18D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
14000

Files In Submission

Name View Source Status
0001558370-22-008120-index-headers.html Edgar Link pending
0001558370-22-008120-index.html Edgar Link pending
0001558370-22-008120.txt Edgar Link pending
0001558370-22-008120-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
omer-20220331.xsd Edgar Link pending
omer-20220331x10q.htm Edgar Link pending
omer-20220331x10q_htm.xml Edgar Link completed
omer-20220331xex10d1.htm Edgar Link pending
omer-20220331xex10d1001.jpg Edgar Link pending
omer-20220331xex31d1.htm Edgar Link pending
omer-20220331xex31d2.htm Edgar Link pending
omer-20220331xex32d1.htm Edgar Link pending
omer-20220331xex32d2.htm Edgar Link pending
omer-20220331_cal.xml Edgar Link unprocessable
omer-20220331_def.xml Edgar Link unprocessable
omer-20220331_lab.xml Edgar Link unprocessable
omer-20220331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending